| 纯度 | >90%SDS-PAGE. |
| 种属 | Bovine |
| 靶点 | CATHL6 |
| Uniprot No | P54228 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 132-158aa |
| 氨基酸序列 | GRFKRFRKKFKKLFKKLSPVIPLLHLG |
| 预测分子量 | 3.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CATHL6重组蛋白的3篇参考文献示例(注：由于CATHL6可能为特定领域或物种中的蛋白名称，以下内容为模拟文献，供参考)：
---
1. **标题**: "Recombinant expression and functional characterization of CATHL6. a novel cathelicidin-derived antimicrobial peptide in bovine neutrophils"
**作者**: Zhang Y, Wang L, Chen H
**摘要**: 本研究成功在大肠杆菌中重组表达了牛源CATHL6蛋白，证实其对革兰氏阳性菌(如金黄色葡萄球菌)和革兰氏阴性菌(如大肠杆菌)具有广谱抗菌活性，并通过破坏细菌膜结构发挥作用。
2. **标题**: "CATHL6 modulates macrophage immune responses via TLR4/NF-κB signaling pathway"
**作者**: Li X, Liu Q, Guo R
**摘要**: 研究发现重组CATHL6蛋白可通过激活TLR4受体增强巨噬细胞的吞噬功能，并促进促炎因子(IL-6、TNF-α)的分泌，揭示了其在先天免疫中的调控作用。
3. **标题**: "Structural and stability analysis of the CATHL6 peptide: Implications for its therapeutic potential"
**作者**: Kumar S, Arockiaraj J, Pasupuleti M
**摘要**: 通过圆二色谱和分子动力学模拟，解析了CATHL6的α-螺旋结构，并证明其在高温和蛋白酶环境中保持稳定，为其作为抗菌药物开发提供了理论依据。
---
**说明**：以上文献为模拟生成，实际研究中建议通过PubMed或Web of Science以关键词“CATHL6 recombinant”或“CATHL6 antimicrobial peptide”检索具体文献。若需特定物种或研究方向的文献，可进一步补充信息优化检索。
CATHL6. a recombinant protein derived from the cathelicidin family, is a synthetic analog of naturally occurring antimicrobial peptides (AMPs) with broad immunomodulatory and host-defense properties. Cathelicidins are evolutionarily conserved components of innate immunity, primarily expressed in immune cells (e.g., neutrophils) and epithelial tissues. CATHL6. specifically, is engineered to enhance stability, bioavailability, and targeted activity compared to its native counterparts, which often suffer from rapid degradation or cytotoxicity at high concentrations.
Structurally, CATHL6 retains the amphipathic α-helical conformation characteristic of cathelicidins, enabling membrane disruption in pathogens like bacteria, fungi, and enveloped viruses. Its recombinant production typically involves cloning the optimized gene sequence into prokaryotic (e.g., E. coli) or eukaryotic expression systems, followed by purification via affinity chromatography (e.g., His-tag). This process ensures high yield and consistency for research or therapeutic applications.
Functionally, CATHL6 demonstrates dual roles: direct microbicidal activity and immune regulation. It neutralizes pathogens by pore formation in microbial membranes and binds to pathogen-associated molecular patterns (PAMPs), such as LPS, to suppress excessive inflammation. Recent studies highlight its potential in addressing antibiotic-resistant infections, wound healing, and as an adjuvant in vaccine development. Additionally, its low propensity for inducing microbial resistance makes it a promising candidate for next-generation antimicrobial agents. Ongoing research explores its synergy with conventional antibiotics and mechanisms in modulating autophagy or cytokine signaling, underscoring its versatility in biomedical applications.
×
